U01DA043809
Cooperative Agreement
Overview
Grant Description
Genetic control of addiction by host and microbiome.
Awardee
Funding Goals
TO SUPPORT BASIC AND CLINICAL NEUROSCIENCE, BIOMEDICAL, BEHAVIORAL AND SOCIAL SCIENCE, EPIDEMIOLOGIC, HEALTH SERVICES AND HEALTH DISPARITY RESEARCH. TO DEVELOP NEW KNOWLEDGE AND APPROACHES RELATED TO THE PREVENTION, DIAGNOSIS, TREATMENT, ETIOLOGY, AND CONSEQUENCES OF DRUG ABUSE AND ADDICTION, INCLUDING HIV/AIDS. TO SUPPORT RESEARCH TRAINING AND RESEARCH SCIENTIST DEVELOPMENT. TO SUPPORT DISSEMINATION OF RESEARCH FINDINGS. SMALL BUSINESS INNOVATION RESEARCH (SBIR) LEGISLATION IS INTENDED TO EXPAND AND IMPROVE THE SBIR PROGRAMS TO EMPHASIZE AND INCREASE PRIVATE SECTOR COMMERCIALIZATION OF TECHNOLOGY DEVELOPED THROUGH FEDERAL SBIR RESEARCH AND DEVELOPMENT, INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN THE SBIR PROGRAM. THE LEGISLATION INTENDS THAT THE SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Connecticut
United States
Geographic Scope
State-Wide
Related Opportunity
Analysis Notes
Amendment Since initial award the End Date has been extended from 07/31/23 to 07/31/24 and the total obligations have increased 388% from $812,782 to $3,967,474.
Jackson Laboratory was awarded
Genetic Control of Addiction by Host and Microbiome
Cooperative Agreement U01DA043809
worth $3,967,474
from National Institute on Drug Abuse in September 2018 with work to be completed primarily in Connecticut United States.
The grant
has a duration of 5 years 10 months and
was awarded through assistance program 93.279 Drug Abuse and Addiction Research Programs.
The Cooperative Agreement was awarded through grant opportunity Identification of Genetic and Genomic Variants by Next-Gen in Sequencing Non-human Animal Models (U01) .
Status
(Complete)
Last Modified 12/5/24
Period of Performance
9/30/18
Start Date
7/31/24
End Date
Funding Split
$4.0M
Federal Obligation
$0.0
Non-Federal Obligation
$4.0M
Total Obligated
Activity Timeline
Subgrant Awards
Disclosed subgrants for U01DA043809
Transaction History
Modifications to U01DA043809
Additional Detail
Award ID FAIN
U01DA043809
SAI Number
U01DA043809-2345289442
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Nonprofit With 501(c)(3) IRS Status (Other Than An Institution Of Higher Education)
Awarding Office
75N600 NIH NATIONAL INSITUTE ON DRUG ABUSE
Funding Office
75N600 NIH NATIONAL INSITUTE ON DRUG ABUSE
Awardee UEI
XR6LMXNKDJJ1
Awardee CAGE
9N885
Performance District
CT-90
Senators
Richard Blumenthal
Christopher Murphy
Christopher Murphy
Budget Funding
Federal Account | Budget Subfunction | Object Class | Total | Percentage |
---|---|---|---|---|
National Institute on Drug Abuse, National Institutes of Health, Health and Human Services (075-0893) | Health research and training | Grants, subsidies, and contributions (41.0) | $4,824,358 | 100% |
Modified: 12/5/24